Showing results (251-260 of 969) with videos related to
Sort By:
Pageof 97
Current Hematologic Malignancy Reports|December 8, 2010
The search for better prognostic models in myelodysplastic syndromesFabio P S Santos, Hagop Kantarjian, Guillermo Garcia-Manero, et al.The Journal of Molecular Diagnostics : JMD|January 23, 2004
Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysisShriHari S Kadkol, Annette Bruno, Carol Dodge, et al.Journal of Hematology & Oncology|June 7, 2020
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directionsBachar Samra, Elias Jabbour, Farhad Ravandi, et al.Journal of Hematology|April 22, 2024
Anorectal Infections in Neutropenic Leukemia Patients: A Common Clinical ChallengeRodrick Babakhanlou, Farhad Ravandi-Kashani, Angel G Hita, et al.Blood|June 17, 2006
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cellsKumudha Balakrishnan, Ramadevi Nimmanapalli, Farhad Ravandi, et al.Cancer|September 6, 2007
Progress in the treatment of acute myeloid leukemiaFarhad Ravandi, Alan K Burnett, Edward D Agura, et al.Future Oncology (London, England)|August 31, 2010
Forodesine: review of preclinical and clinical dataAref Al-Kali, Varsha Gandhi, Mohamad Ayoubi, et al.Annals of Hematology|March 31, 2021
High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cellsZhihong Zeng, Charlie Ly, Naval Daver, et al.Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.Blood Advances|January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosisPrajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.Pageof 97